.png)
.png)
Global Head, Epidemiology & Real World Evidence
ViiV Healthcare
Disclosure(s): ViiV Healthcare: I am full time employee of ViiV Healthcare and receive GlaxoSmithKline stock as part of my compensation package, Stocks/Bonds
Dr. Vani Vannappagari is Global Head of Epidemiology and Real World Evidence at ViiV Healthcare, a joint venture between GlaxoSmithKline and Pfizer that focuses solely on treatment, prevention and cure for HIV. In this role she sets the strategy for conducting studies to collect real world evidence on treatment effectiveness, adherence and safety of the antiretroviral drugs. She also leads studies in pregnancy and registries that evaluate drug safety during pregnancy. She is the industry co-chair of the Antiretroviral Pregnancy Registry steering committee.
Dr. Vannappagari is also an Adjunct Associate Professor at the department of Epidemiology, UNC- Chapel Hill. Prior to joining ViiV Healthcare, she was director of infectious disease epidemiology at GlaxoSmithKline leading epidemiology projects for HIV, Influenza, Anthrax and Malaria drug development. Her work involved disease epidemiology, pharmacovigilance and post marketing drug safety, pregnancy and drug exposure registries. Dr. Vannappagari has MBBS from Karnatak Medical College, and MPH and PhD in epidemiology from the University of North Carolina at Chapel Hill.